Status:
COMPLETED
MACS and Healthy Volunteers Bone Study
Lead Sponsor:
Mayo Clinic
Conditions:
MACS Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Adrenal adenoma is detected in 5-7% of adults and demonstrates mild autonomous cortisol secretion (MACS, dexamethasone suppression test \>1.8 mcg/dl) in 50% of individuals with adenoma. Published repo...
Detailed Description
In this study, we will determine whether patients with MACS (versus healthy age and sex matched controls) demonstrate: 1) decreased bone strength and quality disproportionate to the decrease of bone d...
Eligibility Criteria
Inclusion
- Patients with MACS
- Age 18-no maximum
- exogenous steroids therapy within the last 5 years ( for more than 3 months , prednisone equivalent \>7.5 mg daily)
- steroid hormone replacement therapy
- any drug therapy affecting bone metabolism
- recent fracture
Exclusion
- exogenous steroids therapy within the last 5 years ( for more than 3 months , prednisone equivalent \>7.5 mg daily)
- steroid hormone replacement therapy ( for adrenal insufficiency, hypogonadism, menopause)
- therapy for osteoporosis
- any drug therapy affecting bone metabolism
- comorbidities affecting steroid metabolome or bone metabolism
- recent fracture
Key Trial Info
Start Date :
February 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 11 2023
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT04343560
Start Date
February 21 2019
End Date
December 11 2023
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905